



STUDY PARTICIPATION CARD

KEEP THIS CARD WITH YOU ALWAYS AND SHOW THIS CARD IF YOU NEED MEDICAL ATTENTION

This patient is taking part in a clinical study.
In case of an emergency, kindly seek advice from the Principal Investigator

Study Details:

D702NC00001 Artemide-Biliary02: Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer

Study Drugs:

Rilvegostomig (AZD2936)

Patient Enrollment Code:

E							
---	--	--	--	--	--	--	--

Instructions for the patient:

- At every visit bring this study participation card.
- Inform your study doctor about any problems, discomforts, and/or undesired or worsening medical conditions you have experienced from the time of your last visit.
- Inform or talk to your study doctor about all medications you have taken or any changes to your medications.
- Inform your study doctor/nurse if you have a change in your contact information (address or telephone number).

In case of emergency, hospitalization, or if medical/surgical intervention is needed, or if any changes in the medication of the patient are required, or if you are concerned about potential interactions with other medications, kindly get in touch with the Principal Investigator for more information.

The contact information can be used by patients or healthcare professionals as needed.
The Principal Investigator is the primary line of contact for Emergency Unblinding.

**Contact Name and Telephone Number
for Principal Investigator:**

--

**Other Study Site Contact Name and
Telephone Number:**

--

Name/Address of the Study Site:

--

**Alternate Name and Phone Number for
Emergency Unblinding, in case the
Principal Investigator is not reachable:**

--

A secondary line of contact for Emergency Unblinding only should be used if the Principal Investigator is not reachable.